Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays

Kevin R. Bewley, Naomi S. Coombes, Luc Gagnon, Lorna McInroy, Natalie Baker, Imam Shaik, Julien R. St-Jean, Natalie St-Amant, Karen R. Buttigieg, Holly E. Humphries, Kerry J. Godwin, Emily Brunt, Lauren Allen, Stephanie Leung, Phillip J. Brown, Elizabeth J. Penn, Kelly Thomas, Greg Kulnis, Bassam Hallis, Miles Carroll, Simon Funnell, Sue Charlton

Published: 2021-04-22 DOI: 10.1038/s41596-021-00536-y

SARS-CoV-2

neutralizing antibody

PRNT

MNA

PNA

AI 解读

Author Correction: Full-length sequencing of circular DNA viruses and extrachromosomal circular DNA using CIDER-Seq

Generation of heart-forming organoids from human pluripotent stem cells

Design and fabrication of wearable electronic textiles using twisted fiber-based threads

Activation of mechanoluminescent nanotransducers by focused ultrasound enables light delivery to deep-seated tissue in vivo

Chromatin accessibility profiling by ATAC-seq

Deoxyfluorination of phenols for chemoselective18F-labeling of peptides

Author Correction: cfSNV: a software tool for the sensitive detection of somatic mutations from cell-free DNA

Human primordial germ cell-like cells specified from resetting precursors develop in human hindgut organoids

An inexpensive semi-automated sample processing pipeline for cell-free RNA extraction

Application of CHyMErA Cas9-Cas12a combinatorial genome-editing platform for genetic interaction mapping and gene fragment deletion screening

查看全部

Sections

Figures

References

Virus neutralization assays measure neutralizing antibodies in serum and plasma, and the plaque reduction neutralization test (PRNT) is considered the gold standard for measuring levels of these antibodies for many viral diseases. We have developed proced
Introduction
Materials
Procedure
Timing
Anticipated results
References
ACKNOWLEDGMENTS

Lim, Y. X., Ng, Y. L., Tam, J. P. & Liu, D. X. Human coronaviruses: a review of virus–host interactions. Diseases https://doi.org/10.3390/diseases4030026 (2016).
Agency, E. M. ICH Topic Q 2 (R1) Validation of analytical procedures: text and methodology (CPMP/ICH/381/95) (EMA 1995).
Zheng, J. SARS-CoV-2: an emerging coronavirus that causes a global threat. Int. J. Biol. Sci. 16, 1678–1685 (2020).
Campi-Azevedo, A. C. et al. 17DD yellow fever revaccination and heightened long-term immunity in populations of disease-endemic areas, Brazil. Emerg. Infect. Dis. 25, 1511–1521 (2019).
Cohen, B. J., Doblas, D. & Andrews, N. Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination. Vaccine 26, 6392–6397 (2008).
Eyal, O. et al. Development of a tissue-culture-based enzyme-immunoassay method for the quantitation of anti-vaccinia-neutralizing antibodies in human sera. J. Virol. Methods 130, 15–21 (2005).
Duan, K. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl Acad. Sci. USA 117, 9490–9496 (2020).
Chi, X. et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 369, 650–655 (2020).
Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450–456 (2020).
Zhao, H. et al. Tocilizumab combined with favipiravir in the treatment of COVID-19: a multicenter trial in a small sample size. Biomed. Pharmacother. 133, 110825 (2021).
Cohen, B. J., Audet, S., Andrews, N., Beeler, J. & WHO Working Group on Measles Plaque Reduction Neutralization Test. Plaque reduction neutralization test for measles antibodies: description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine 26, 59–66 (2007).
Fournier, C. et al. A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies. Virol. J. 4, 35 (2007).
Simoes, M. et al. Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies. Biologicals 40, 399–404 (2012).
Vaidya, S. R. et al. Development of a focus reduction neutralization test (FRNT) for detection of mumps virus neutralizing antibodies. J. Virol. Methods 163, 153–156 (2010).
Steeds, K. et al. Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies. Sci. Rep. 10, 14289 (2020).
National Institute for Biological Standards and Control (NIBSC). Coronavirus (COVID-19)-related research reagents available from the NIBSC. https://www.nibsc.org/science_and_research/idd/cfar/covid-19_reagents.aspx
Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 396, 467–478 (2020).
Ramasamy, M. N. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet https://doi.org/10.1016/S0140-6736(20)32466-1 (2020).
Sadoff, J. et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. Preprint at medRxiv https://doi.org/10.1101/2020.09.23.20199604 (2020).
Ryan, K. A. et al. Dose-dependent response to infection with SARS-CoV-2 in the ferret model: evidence of protection to re-challenge. Preprint at bioRxiv https://doi.org/10.1101/2020.05.29.123810 (2020).
Salguero, F. J. et al. Comparison of Rhesus and Cynomolgus macaques as an authentic model for COVID-19. Preprint at bioRxiv https://doi.org/10.1101/2020.09.17.301093 (2020).
Smith, T. R. F. et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 11, 2601 (2020).
Tree, J. A. et al. Unfractionated heparin inhibits live wild-type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations. Br. J. Pharmacol. https://doi.org/10.1111/bph.15304 (2020).
Huo, J. et al. Neutralization of SARS-CoV-2 by destruction of the prefusion spike. Cell Host Microbe 28, 497 (2020).
Ejemel, M. et al. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. Nat. Commun. 11, 4198 (2020).
Zhou, D. et al. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat. Struct. Mol. Biol. 27, 950–958 (2020).
Nie, J. et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat. Protoc. 15, 3699–3715 (2020).
Tandon, R. et al. Effective inhibition of SARS-CoV-2 entry by heparin and enoxaparin derivatives. Preprint at bioRxiv https://doi.org/10.1101/2020.06.08.140236 (2020).
Armitage, P. & Allen, I. Methods of estimating the LD 50 in quantal response data. J. Hyg. (Lond) 48, 298–322 (1950).
Amanat, F. et al. An in vitro microneutralization assay for SARS-CoV-2 serology and drug screening. Curr. Protoc. Microbiol. 58, e108 (2020).
Vanderheiden, A. et al. Development of a rapid focus reduction neutralization test assay for measuring SARS-CoV-2 neutralizing antibodies. Curr. Protoc. Immunol. 131, e116 (2020).

Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays

Extended

Supplementary information

推荐阅读